Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1999 October; 81(3): 542–548.
PMCID: PMC2362920

Regular use of analgesics is a risk factor for renal cell carcinoma


Phenacetin-based analgesics have been linked to the development of renal pelvis cancer and renal cell carcinoma (RCC). The relationship between non-phenacetin types of analgesics and kidney cancer is less clear, although laboratory evidence suggests that these drugs possess carcinogenic potential. A population-based case–control study involving 1204 non-Asian RCC patients aged 25–74 and an equal number of sex-, age- and race-matched neighbourhood controls was conducted in Los Angeles, California, to investigate the relationship between sustained use of analgesics and risk of RCC according to major formulation categories. Detailed information on medical and medication histories, and other lifestyle factors was collected through in-person interviews. Regular use of analgesics was a significant risk factor for RCC in both men and women (odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.4–1.9 for both sexes combined). Risks were elevated across all four major classes of analgesics (aspirin, non-steroidal anti-inflammatory agents other than aspirin, acetaminophen and phenacetin). Within each class of analgesics, there was statistically significant increasing risk with increasing level of exposure. Although there was some minor variability by major class of formulation, in general individuals in the highest exposure categories exhibited approximately 2.5-fold increase in risk relative to non- or irregular users of analgesics. Subjects who took one regular-strength (i.e. 325 mg) aspirin a day or less for cardiovascular disease prevention were not at an increased risk of RCC (OR = 0.9, 95% CI = 0.6–1.4). © 1999 Cancer Research Campaign

Keywords: renal cell cancer, analgesics, NSAID, aspirin, acetaminophen, phenacetin

Full Text

The Full Text of this article is available as a PDF (83K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Adams DH, Howie AJ, Michael J, McConkey B, Bacon PA, Adu D. Non-steroidal anti-inflammatory drugs and renal failure. Lancet. 1986 Jan 11;1(8472):57–60. [PubMed]
  • Armstrong B, Garrod A, Doll R. A retrospective study of renal cancer with special reference to coffee and animal protein consumption. Br J Cancer. 1976 Feb;33(2):127–136. [PMC free article] [PubMed]
  • Asal NR, Geyer JR, Risser DR, Lee ET, Kadamani S, Cherng N. Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions. Cancer Detect Prev. 1988;13(3-4):263–279. [PubMed]
  • Bengtsson U, Angervall L, Ekman H, Lehmann L. Transitional cell tumors of the renal pelvis in analgesic abusers. Scand J Urol Nephrol. 1968;2(3):145–150. [PubMed]
  • BRODIE BB, AXELROD J. The fate of acetophenetidin in man and methods for the estimation of acetophenetidin and its metabolites in biological material. J Pharmacol Exp Ther. 1949 Sep;97(1):58–67. [PubMed]
  • Burrell JH, Yong JL, Macdonald GJ. Analgesic nephropathy in Fischer 344 rats: comparative effects of chronic treatment with either aspirin or paracetamol. Pathology. 1991 Apr;23(2):107–114. [PubMed]
  • Derby LE, Jick H. Acetaminophen and renal and bladder cancer. Epidemiology. 1996 Jul;7(4):358–362. [PubMed]
  • Devesa SS, Silverman DT, McLaughlin JK, Brown CC, Connelly RR, Fraumeni JF., Jr Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control. 1990 Sep;1(2):133–141. [PubMed]
  • Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994 Oct;107(4):1183–1188. [PubMed]
  • Emeigh Hart SG, Beierschmitt WP, Bartolone JB, Wyand DS, Khairallah EA, Cohen SD. Evidence against deacetylation and for cytochrome P450-mediated activation in acetaminophen-induced nephrotoxicity in the CD-1 mouse. Toxicol Appl Pharmacol. 1991 Jan;107(1):1–15. [PubMed]
  • Flaks A, Flaks B. Induction of liver cell tumours in IF mice by paracetamol. Carcinogenesis. 1983;4(4):363–368. [PubMed]
  • Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995 Sep 7;333(10):609–614. [PubMed]
  • Gobé GC, Axelsen RA. The role of apoptosis in the development of renal cortical tubular atrophy associated with healed experimental renal papillary necrosis. Pathology. 1991 Jul;23(3):213–223. [PubMed]
  • Henderson BE, Ross RK, Pike MC. Toward the primary prevention of cancer. Science. 1991 Nov 22;254(5035):1131–1138. [PubMed]
  • Jensen OM, Knudsen JB, Tomasson H, Sørensen BL. The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. Int J Cancer. 1989 Dec 15;44(6):965–968. [PubMed]
  • Johansson SL. Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int J Cancer. 1981;27(4):521–529. [PubMed]
  • Kari F, Bucher J, Haseman J, Eustis S, Huff J. Long-term exposure to the anti-inflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in mice. Jpn J Cancer Res. 1995 Mar;86(3):252–263. [PubMed]
  • Kokmen E, Beard CM, O'Brien PC, Offord KP, Kurland LT. Is the incidence of dementing illness changing? A 25-year time trend study in Rochester, Minnesota (1960-1984) Neurology. 1993 Oct;43(10):1887–1892. [PubMed]
  • Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993 Mar;4(2):101–110. [PubMed]
  • Kyle ME, Kocsis JJ. The effect of age on salicylate-induced nephrotoxicity in male rats. Toxicol Appl Pharmacol. 1985 Nov;81(2):337–347. [PubMed]
  • McCredie M, Ford JM, Taylor JS, Stewart JH. Analgesics and cancer of the renal pelvis in New South Wales. Cancer. 1982 Jun 15;49(12):2617–2625. [PubMed]
  • McCredie M, Ford JM, Stewart JH. Risk factors for cancer of the renal parenchyma. Int J Cancer. 1988 Jul 15;42(1):13–16. [PubMed]
  • McCredie M, Stewart JH, Day NE. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer. 1993 Jan 21;53(2):245–249. [PubMed]
  • McCredie M, Pommer W, McLaughlin JK, Stewart JH, Lindblad P, Mandel JS, Mellemgaard A, Schlehofer B, Niwa S. International renal-cell cancer study. II. Analgesics. Int J Cancer. 1995 Jan 27;60(3):345–349. [PubMed]
  • McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996 Aug;47(2):425–432. [PubMed]
  • McLaughlin JK, Blot WJ, Mehl ES, Fraumeni JF., Jr Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst Monogr. 1985 Dec;69:217–222. [PubMed]
  • Phenacetin and cancers of the urinary tract. N Engl J Med. 1985 Dec 5;313(23):1479–1480. [PubMed]
  • McMurtry RJ, Snodgrass WR, Mitchell JR. Renal necrosis, glutathione depletion, and covalent binding after acetaminophen. Toxicol Appl Pharmacol. 1978 Oct;46(1):87–100. [PubMed]
  • Mahony JF, Storey BG, Ibañez RC, Stewart JH. Analgesic abuse, renal parenchymal disease and carcinoma of the kidney or ureter. Aust N Z J Med. 1977 Oct;7(5):463–469. [PubMed]
  • Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol. 1994 Oct;23(5):923–930. [PubMed]
  • Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989 Jun;37(6):549–555. [PubMed]
  • Mitchell JR, McMurtry RJ, Statham CN, Nelson SD. Molecular basis for several drug-induced nephropathies. Am J Med. 1977 Apr;62(4):518–526. [PubMed]
  • Nakanishi K, Kurata Y, Oshima M, Fukushima S, Ito N. Carcinogenicity of phenacetin: long-term feeding study in B6c3f1 mice. Int J Cancer. 1982 Apr 15;29(4):439–444. [PubMed]
  • Nanra RS. Renal effects of antipyretic analgesics. Am J Med. 1983 Nov 14;75(5A):70–81. [PubMed]
  • Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989 Nov 18;299(6710):1247–1250. [PMC free article] [PubMed]
  • Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. [PubMed]
  • Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994 Dec 22;331(25):1675–1679. [PubMed]
  • Plummer DT, Leathwood PD, Blake ME. Urinary enzymes and kidney damage by aspirin and phenacetin. Chem Biol Interact. 1975 Apr;10(4):277–284. [PubMed]
  • Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, Klimpel A, Borner K, Molzahn M. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol. 1989;9(5):403–412. [PubMed]
  • Prescott LF. Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs. 1982 Jan-Feb;23(1-2):75–149. [PubMed]
  • Rosenberg L, Rao RS, Palmer JR, Strom BL, Zauber A, Warshauer ME, Stolley PD, Shapiro S. Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control. 1998 Jan;9(1):83–88. [PubMed]
  • Ruffin MT, 4th, Krishnan K, Rock CL, Normolle D, Vaerten MA, Peters-Golden M, Crowell J, Kelloff G, Boland CR, Brenner DE. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst. 1997 Aug 6;89(15):1152–1160. [PubMed]
  • Sabatini S. Pathophysiologic mechanisms in analgesic-induced papillary necrosis. Am J Kidney Dis. 1996 Jul;28(1 Suppl 1):S34–S38. [PubMed]
  • Sandler DP, Smith JC, Weinberg CR, Buckalew VM, Jr, Dennis VW, Blythe WB, Burgess WP. Analgesic use and chronic renal disease. N Engl J Med. 1989 May 11;320(19):1238–1243. [PubMed]
  • Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991 Aug 1;115(3):165–172. [PubMed]
  • Segasothy M, Samad SA, Zulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis. 1994 Jul;24(1):17–24. [PubMed]
  • Tsuda H, Sakata T, Masui T, Imaida K, Ito N. Modifying effects of butylated hydroxyanisole, ethoxyquin and acetaminophen on induction of neoplastic lesions in rat liver and kidney initiated by N-ethyl-N-hydroxyethylnitrosamine. Carcinogenesis. 1984 Apr;5(4):525–531. [PubMed]
  • Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer. 1998 May;77(9):1508–1513. [PMC free article] [PubMed]
  • Yuan JM, Castelao JE, Gago-Dominguez M, Yu MC, Ross RK. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):429–433. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK